A rapid generation of adenovirus vector with a genetic modification in hexon protein

Journal of Biotechnology

Volumn 157, Issue 3, 2012, Pages 373-378

  Di, Bingyan ^a   Mao, Qinwen ^b   Zhao, Junli ^a   Li, Xing ^a   Wang, Dongyang ^a   Xia, Haibin ^a  

^a SHAANXI NORMAL UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adenoviral vector; Directional cloning; Gene therapy; Hexon modification; Quick screening

Indexed keywords

ADENOVIRAL VECTORS; ADENOVIRUS VECTOR; CANCER GENE THERAPY; CMV PROMOTER; DIRECTIONAL CLONING; EXPRESSION CASSETTE; GENETIC MODIFICATIONS; GENETICALLY MODIFIED; HEXON MODIFICATION; IN-VITRO; ONE STEP; REGION FUNCTION; RESTRICTION ENZYMES; STICKY ENDS; TRANSDUCTION EFFICIENCY;

ENZYMES; GENE THERAPY; GENETIC ENGINEERING; VIRUSES;

VECTORS;

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; ASPARAGINYLGLYCLARGININE; BETA GALACTOSIDASE; HEXON PROTEIN; PEPTIDE; PROTEIN; RESTRICTION ENDONUCLEASE; TAT PROLYLTHREONYLASPARTIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA MODIFICATION; FEMALE; GENE INSERTION; GENETIC PROCEDURES; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; ONE STEP LIGATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUICK WHITE BLUE COLOR SCREENING; TROPISM;

ADENOVIRIDAE; CAPSID PROTEINS; CELL LINE, TUMOR; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; RESTRICTION MAPPING;

ADENOVIRIDAE;

EID: 84862830842     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2011.12.022     Document Type: Article

References (46)

1. Abe S., Okuda K., Ura T., Kondo A., Yoshida A., Yoshizaki S., Mizuguchi H., Klinman D., Shimada M. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J. Gene Med. 2009, 11:570-579.
2. Barnett B.G., Crews C.J., Douglas J.T. Targeted adenoviral vectors. Biochim. Biophys. Acta 2002, 1575:1-14.
3. Benihoud K., Yeh P., Perricaudet M. Adenovirus vectors for gene delivery. Curr. Opin. Biotechnol. 1999, 10:440-447.
4. Benkö M., Harrach B. Molecular evolution of adenoviruses. Curr. Top. Microbiol. Immunol. 2003, 272:3-35.
5. Bryan R.Meade, Dowdy S.F. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 2007, 59:134-140.
6. Coyne C.B., Bergelson J.M. CAR: a virus receptor within the tight junction. Adv. Drug Deliv. Rev. 2005, 57:869-882.
7. Crompton J., Toogood C.I.A., Wallis N., Hay R.T. Expression of a foreign epitope on the surface of the adenovirus hexon. J. Gen. Virol. 1994, 75:133-139.
8. Davison A.J., Benkö M., Harrach B. Genetic content and evolution of adenoviruses. J. Gen. Virol. 2003, 84:2895-2908.
9. De Jong J.C., Wermenbol A.G., Verweij-Uijterwaal M.W., Slaterus K.W., Wertheim-Van Dillen P., Van Doornum G.J.J., Khoo S.H., Hierholzer J.C. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J. Clin. Microbiol. 1999, 37:3940-3945.
10. Einfeil D.A., Brough D.E., Roelvink P.W., Kovesdi I., Wickham T.J. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J. Virol. 1999, 73:9130-9136.
11. Fonseca S.B., Pereira M.P., Kelley S.O. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 2009, 61:953-964.
12. Gahéry-Ségard H., Farace F., Godfrin D., Gaston J., Lengagne R., Tursz T., Boulanger P., Guillet J.G. Immune response to recombinant capsid proteins of adenovirus in human: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 1998, 72:2388-2397.
13. Gall J., Kass-Eisler A., Leinwand L., Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 1996, 70:2116-2123.
14. Gall J.G.D., Crystal R.G., Falck-Pedersen E. Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J. Virol. 1998, 72:10260-10264.
15. Han T., Tang Y., Ugai H., Perry L.E., Siegal G.P., Contreras J.L., Wu H. Genetic incorporation of the protein transduction domain of Tat into Ad5 fiber enhances gene transfer efficacy. Virol. J. 2007, 4:103.
16. Jullienne B., Vigant F., Muth E., Chaligné R., Bouquet C., Giraudier S., Perricaudet M., Benihoud K. Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid. Gene Ther. 2009, 16:1405-1415.
17. Kim M., Zinn K.R.B., Barnett G., Sumerel L.A., Krasnykh V., Curiel D.T., Douglas J.T. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur. J. Cancer 2002, 38:1917-1926.
18. Krasnykh V.N., Mikheeva G.V., Douglas J.T., Curiel D.T. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 1996, 70:6839-6846.
19. Krasnykh V.N., Dmitriev I., Mikheeva G., Ryan Miller C., Belousova N., Curiel D.T. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 1998, 72:1844-1852.
20. Krasnykh V.N., Douglas J.T., van Beusechem V.W. Genetic targeting of adenoviral vectors. Mol. Ther. 2000, 1:391-405.
21. Kurachi S., Koizumi N., Sakurai F., Kawabata K., Sakurai H., Nakagawa S., Hayakawa T., Mizuguchi H. Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon. Gene Ther. 2007, 14:266-274.
22. Kurachi S., Tashiro K., Sakurai F., Sakurai H., Kawabata K., Yayama K., Okamoto H., Nakagawa S., Mizuguchi H. Fiber-modified adenovirus vectors containing the TAT peptide derived from HIV-1 in the fiber knob have efficient gene transfer activity. Gene Ther. 2007, 14:1160-1165.
23. Liu S., Mao Q., Zhang W., Zheng X., Bian Y., Wang D., Chai L.H., Zhao J.L., Xia H. Genetically modified adenoviral vector with the protein transduction domain of Tat improves gene transfer to CAR-deficient cells. Biosci. Rep. 2009, 29:103-109.
24. Meier O., Greber U.F. Adenovirus endocytosis. J. Gene Med. 2004, 6(Suppl 1):S152-S163.
25. Mizuguchi H., Hayakawa T. Targeted adenovirus vectors. Hum. Gene Ther. 2004, 15:1034-1044.
26. Molinier-Frenkel V., Lengagne R., Gaden F., Hong S.-S., Choppin J., Gahery-Ségard H., Boulanger P., Guillet J.-G. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 2002, 76:127-135.
27. Nemerow G.R. Adenoviral vectors-new insights. Trends Microbiol. 2000, 8:391-394.
28. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., Liu J., Thorner A.R., Swanson P.E., Gorgone D.A., Lifton M.A., Lemckert A.A., Holterman L., Chen B., Dilraj A., Carville A., Mansfield K.G., Goudsmit J., Barouch D.H. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441:239-243.
29. Roelvink P.W., Lizonova A., Lee J.G.M., Li Y., Bergelson J.M., Finberg R.W., Brough D.E., Kovesdi I., Wickham T.J. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. 1998, 72:7909-7915.
30. Roy S., Shirley P.S., McClelland A., Kaleko M. Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol. 1998, 72:6875-6879.
31. Siegfried W. Perspectives in gene therapy with recombinant adenoviruses. Exp. Clin. Endocrinol. 1993, 101:7-11.
32. Stewart P.L., Fuller S.D., Burnett R.M. Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J. 1993, 12:2589-2599.
33. Tomko R.P., Xu R., Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:3352-3356.
34. van Oostrum J., Burnett R.M. Molecular composition of the adenovirus type 2 virion. J. Virol. 1985, 56:439-448.
35. Vellinga J., Van der Heijdt S., Hoeben R.C. The adenovirus capsid: major progress in minor proteins. J. Gen. Virol. 2005, 86:1581-1588.
36. Vigne E., Mahfouz I., Dedieu J.F., Brie A., Perricaudet M., Yeh P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol. 1999, 73:5156-5161.
37. Vorburger S.A., Hunt K.K. Adenoviral gene therapy. Oncologist 2002, 7:46-59.
38. Waddington S.N., McVey J.H., Bhella D., Parker A.L., Barker K., Atoda H., Pink R., Buckley S.M., Greig J.A., Denby L., Custers J., Morita T., Francischetti I.M., Monteiro R.Q., Barouch D.H., van Rooijen N., Napoli C., Havenga M.J., Nicklin S.A., Baker A.H. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132:397-409.
39. Wadia J.S., Dowdy S.F. Protein transduction technology. Curr. Opin. Biotechnol. 2002, 13:52-56.
40. Wang D., Liu S., Mao Q., Zhao J., Xia H. A novel vector for a rapid generation of fiber-mutant adenovirus based on one step ligation and quick screening of positive clones. J. Biotechnol. 2011, 152:72-76.
41. Wickham T.J., Roelvink P.W., Brough D.E., Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol. 1996, 14:1570-1573.
42. Wickham T.J. Targeting adenovirus. Gene Ther. 2000, 7:110-114.
43. Wu H., Han T., Belousova N., Krasnykh V., Kashentseva E., Dmitriev I., Kataram M., Mahasreshti P.J., Curiel D.T. Identification of sites in adenovirus hexon for foreign peptide incorporation. J. Virol. 2005, 79:3382-3390.
44. Xia H., Anderson B., Mao Q., Davidson B.L. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J. Virol. 2000, 74:11359-11366.
45. Yang Y., Li Q., Ertl H.C.J., Wilson J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 1995, 69:2004-2015.
46. Zaiss A.-K., Liu Q., Bowen G.P., Wong N.C.W., Bartlett J.S., Muruve D.A. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 2002, 76:4580-4590.